Cargando…
Low-Dose Abiraterone, a Rare European Commodity
Autores principales: | Peters, Niamh, Zameer, Mohammed Zeeshan, O'Reilly, Seamus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268895/ https://www.ncbi.nlm.nih.gov/pubmed/32427502 http://dx.doi.org/10.1200/GO.20.00106 |
Ejemplares similares
-
Potential Cost Savings With Low-Dose Abiraterone in the United States
por: Premnath, Naveen, et al.
Publicado: (2020) -
Fulvestrant-Big Mac Index: Defining Inequality in Oncology
por: O'Reilly, David, et al.
Publicado: (2021) -
Health Care: Neither Right, Privilege nor Commodity
por: Klunk, Christopher
Publicado: (2022) -
Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015) -
Is flat dosing cost-effective? Re: ‘The same old story’: thoughts on
authorised doses of anticancer drugs
por: Farooq, Abdul R., et al.
Publicado: (2020)